Takeda Pharmaceuticals America and Affymax have entered into a supply agreement for sourcing and supply of Omontys (peginesatide) Injection to Fresenius Medical Care North America and certain affiliates. Omontys, a once-monthly erythropoiesis-stimulating agent (ESA) for anemia, will now be available to dialysis patients with chronic kidney disease (CKD) in the U.S.   The agreement, which ends in April 2013, allows Fresenius Medical Care North America to purchase Omontys for use in U.S. centers w...